title: Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
authors.affiliation: a Division of Oncology , Washington University School of Medicine , St. Louis , MO , USA ;
authors.forename: Armin
authors.initials: A
authors.lastname: Rashidi
authors.affiliation: a Division of Oncology , Washington University School of Medicine , St. Louis , MO , USA ;
authors.forename: Eunhye
authors.initials: E
authors.lastname: Oak
authors.affiliation: a Division of Oncology , Washington University School of Medicine , St. Louis , MO , USA ;
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Carson
authors.affiliation: a Division of Oncology , Washington University School of Medicine , St. Louis , MO , USA ;
authors.forename: Nina D
authors.initials: ND
authors.lastname: Wagner-Johnston
authors.affiliation: b Department of Pathology and Immunology , Washington University School of Medicine , St. Louis , MO , USA.
authors.forename: Friederike
authors.initials: F
authors.lastname: Kreisel
authors.affiliation: a Division of Oncology , Washington University School of Medicine , St. Louis , MO , USA ;
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Bartlett
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone